Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States radiologic technologists study
International Journal of Cancer, 04/19/2012
Cahoon EK et al. – Any Nonsteroidal anti–inflammatory drugs (NSAIDs) use was not associated with subsequent incidence of basal cell carcinoma (BCC) after adjusting for age, sex and estimated lifetime summer sun exposure. Neither association was observed when stratified by NSAID type (aspirin and other NSAIDs), nor did dose–response patterns emerge by frequency of use (average days per month). Further analyses did not reveal interaction with sex, birth cohort, smoking, alcohol consumption, sun exposure, occupational radiation exposure or personal risk factors for BCC.
In the United States Radiologic Technologists cohort, the authors followed subjects to assess NSAID use on risk of first incident BCC.
They included Caucasian participants who responded to both second and third questionnaires (administered from 1994 to 1998 and 2003 to 2005, respectively), and who reported no cancer at the time of the second questionnaire, N=58,213.
BCC, constituent risk factors (e.g., eye color, complexion, hair color) and sun exposure history were assessed through self-administered survey.
Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models.
Of the 58,213 people in the study population, 2,291 went on to develop BCC.
Any NSAID use was not associated with subsequent incidence of BCC (HR=1.04, 95% CI: 0.92-1.16) after adjusting for age, sex and estimated lifetime summer sun exposure.
Neither association was observed when stratified by NSAID type (aspirin and other NSAIDs), nor did dose–response patterns emerge by frequency of use (average days per month).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.